Table 3.
Outcomes in patients with CRE infections.
| CPE (n=253) | Non-CP-CRE (n=102) | U-CRE (n=94) | All (n=449) | P value | |
|---|---|---|---|---|---|
| DOOR at 30 days | n/ad | ||||
| alive without events | 106 (42) | 37 (36) | 40 (43) | 183 (41) | |
| alive with 1 event | 53 (21) | 26 (25) | 18 (19) | 97 (22) | |
| alive with 2 or 3 events | 31 (12) | 17 (17) | 14 (15) | 62 (14) | |
| dead | 63 (25) | 22 (22) | 22 (23) | 107 (24) | |
| DOOR components at 30 daysa | |||||
| not discharged | 103 (41) | 45 (44) | 36 (38) | 184 (41) | 0·70 |
| readmitted | 32 (13) | 12 (12) | 14 (15) | 58 (13) | 0·79 |
| lack of clinical response | 86 (34) | 35 (34) | 32 (34) | 153 (34) | >0·99 |
| lack of symptomatic response | 74 (29%) | 29 (28) | 28 (30) | 131 (29) | 0·98 |
| relapse | 12 (5) | 3 (3) | 3 (3) | 18 (4) | 0·66 |
| remains on anti-CRE antibiotic | 8 (3) | 9 (9) | 7 (7) | 24 (5) | 0·06 |
| renal failure | 13 (5) | 5 (5) | 5 (5) | 23 (5) | 0·99 |
| C. difficile infection | 3 (1) | 2 (2) | 0 (0) | 5 (1) | 0·42 |
| LOS, days, median (IQR) | 19 (9, 38) | 29 (12, 60) | 15 (6, 35) | 20 (8, 45) | 0·002 |
| Post-culture LOS, days, median (IQR) | 11 (5, 22) | 16 (6, 26) | 10 (4, 19) | 12 (5, 23) | 0·02 |
| 30-day mortality | 63 (25) | 22 (22) | 22 (23) | 107 (24) | 0·80 |
| 90-day mortality | 79 (31) | 33 (32) | 25 (27) | 137 (31) | 0·64 |
| 90-day readmissionsb | 81/183 (44%) | 37/69 (54%) | 32/73 (44%) | 150/325 (46%) | 0·37 |
| clinical response | 167 (66%) | 67 (66%) | 62 (66%) | 296 (66%) | >0·99 |
| Dispositionc | 0·03 | ||||
| death | 63 (25) | 27 (26) | 19 (20) | 109 (24) | |
| home | 72 (28) | 38 (37) | 40 (43) | 150 (33) | |
| hospice | 7 (3) | 6 (6) | 2 (2) | 15 (3) | |
| long term acute care | 29 (11) | 7 (7) | 2 (2) | 38 (8) | |
| long term care | 71 (28) | 21 (21) | 24 (26) | 116 (26) | |
| transfer other hospital | 11 (4) | 3 (3) | 6 (6) | 20 (4) | |
| transferred to a foreign country | 0 (0) | 0 (0) | 1 (1) | 1 (<1) |
Desirability of outcome ranking (DOOR) analysis components as defined in Supplementary Materials.
in patients discharged alive. LOS length of hospital stay.
Grouped for analysis purposes as death/hospice, home/transferred to a foreign country, LTAC/transfer other hospital, long-term care.
Inverse probability weighted (IPW) DOOR analyses indicated no significant differences between groups. IPW-adjusted probabilities of a patient with CPE vs. non-CP-CRE, CPE vs. U-CRE, non-CP-CRE vs U-CRE having a better outcome are 52% (95% CI 45%–58%), 52% (95% CI 44%–61%), 51% (95% CI 41%–60%). CPE: carbapenemase-producing Enterobacteriaceae. Non-CP-CRE: non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE). U-CRE: unconfirmed CRE.